|Product Description||SARS-CoV-2 Spike (Omicron BA.2) Fluc-GFP Pseudovirus|
|Envelope protein||SARS-CoV-2 Spike Protein (Omicron BA.2 | B.1.1.529)|
|Physical appearance||Dark red-brown transparent liquid|
Pseudovirus Neutralization Assay
a. Mix 89% DMEM medium, 10% Fetal bovine serum and 1% Penicillin-Streptomycin to prepare complete DMEM medium.
b. Thaw the pseudovirus at room temperature. Dilute the pseudovirus with complete DMEM medium according to your pre-test results. In general, we recommend 125-fold dilution if you use the same materials and luminescence meter as those in this protocol (e. g., 20 μL Pseudovirus + 2.48 mL complete DMEM medium).
c. Dilute your samples with complete DMEM medium in a 96-well white flat bottom plate to reach a volume of 75 μL per well, then add 25 μL pseudovirus suspension per well to reach a final volume of 100 μL per well. Gently flap to mix well. Incubate the plate in a 5% (vol/vol) CO2, 37°C incubator for 60 min.
d. Digest and resuspend HEK293/Human ACE2 Overexpression Stable Cells (ACROBiosystems, Cat. No. CHEK-ATP042) with complete DMEM medium. Adjust the cell density to 4 ~ 5 × 105 cells per milliliter with complete DMEM medium. Seed 100 μL the cell suspension per well into the 96-well plate. Gently flap to mix well. Incubate the plate in a 5% (vol/vol) CO2, 37°C incubator for 48 h.
e. Prepare the detection reagent (britelite plus Reporter Gene Assay System (PerkinElmer, Cat. No. 6066761)) and balance it to room temperature.
f. Take out the 96-well plate and discard 100 μL medium per well. Balance the plate to room temperature for 10 min. Add 100 μL detection reagent and mix well. Incubate for 2 min at room temperature.
g. Read the luminescence values (RLU) of the wells with a luminescence meter (PerkinElmer, Cat. No. HH34000000).
SARS-CoV-2 Spike (Omicron BA.2) Fluc-GFP Pseudovirus uses pseudotyped HIV-1 virus with firefly luciferase and green fluorescent protein (GFP) gene as the backbone and takes SARS-CoV-2 spike protein as its envelope protein. It can effectively infect human ACE2 overexpressing cells and can be used in determining neutralizing antibody titer, screening for inhibitors of the Spike-ACE2 interaction, studying virus invasion and COVID-19 vaccine development.
Mutation(s) compared to wild type surface glycoprotein [severe acute respiratory syndrome coronavirus 2] (Accession # QHD43416.1): T19I, LPP24-26del, A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K ("LPP24-26del, A27S" equals to "L24S, PPA25-27del").
a. Though pseudovirus particles has no pathogenicity and cannot replicate, the assays should be carried out carefully in a Biosafety Level 2 or higher-level laboratory with a biosafety cabinet.
b. Serum samples from animals or humans should be inactivated in a water bath at 56°C for 30 min before being tested.
c. Please avoid freezing and thawing, which would influence the titer of the pseudovirus.
d. The product is for Research Use Only.
For more information and advice, please check the Data Sheet of this product.
Optional Relative Products
HEK293/Human ACE2 Stable Cell Line (ACROBiosystems, Cat. No. CHEK-ATP042)
The stable cell line is susceptible to SARS-CoV-2 Spike Fluc-GFP Pseudovirus.
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (ACROBiosystems, Cat. No. S1N-M122)
The antibody is an ideal positive control for neutralization assay of wild type and multiple kinds of mutant SARS-CoV-2 Spike pseudovirus.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $980.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.